Indication
Urothelial Carcinoma
34 clinical trials
38 products
12 drugs
Clinical trial
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)Status: Recruiting, Estimated PCD: 2025-01-23
Product
M6223Product
AvelumabProduct
Sacituzumab GovitecanProduct
NKTR-255Product
TYRA-300Clinical trial
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)Status: Recruiting, Estimated PCD: 2026-11-01
Product
TJ271Clinical trial
A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination With Pembrolizumab in Chinese Patients With Advanced Solid TumorsStatus: Withdrawn, Estimated PCD: 2023-12-31
Clinical trial
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaStatus: Terminated, Estimated PCD: 2022-08-03
Product
SitravatinibProduct
NivolumabProduct
PembrolizumabProduct
Enfortumab vedotinClinical trial
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving ErdafitinibStatus: Terminated, Estimated PCD: 2022-12-20
Product
BalversaProduct
MitomycinClinical trial
uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With JelmytoStatus: Recruiting, Estimated PCD: 2025-04-01
Product
JelmytoClinical trial
A Phase 1/2, Open-label, Dose-exploration and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTX-301 Monotherapy in Advanced Solid Tumours, and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer, and in Combination With Temozolomide as Adjuvant (Maintenance) Therapy in High-grade Glioma (Optional Arm)Status: Terminated, Estimated PCD: 2022-11-08
Product
TemozolomideProduct
NTX-301Product
Platinum-based ChemotherapyClinical trial
Phase II Randomized Trial of Immunotherapy Versus Immunotherapy and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (IMMORTAL)Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Clinical trial
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaStatus: Recruiting, Estimated PCD: 2026-01-01
Product
PropranololClinical trial
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 TherapyStatus: Recruiting, Estimated PCD: 2027-08-15
Drug
DocetaxelDrug
cyclophosphamideProduct
EribulinDrug
GemcitabineDrug
TiragolumabProduct
Neoantigen Peptide VaccineClinical trial
A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Urothelial CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Product
RelatlimabClinical trial
RESOLVE : A Phase I Trial of Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancers With Focus on Urothelial CarcinomaStatus: Recruiting, Estimated PCD: 2024-11-30
Product
BelinostatClinical trial
Phase I Study of WST11 Phototherapy for Upper Tract Urothelial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-02
Product
DurvalumabClinical trial
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal InsufficiencyStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Phase II, Multicenter, Non-randomized, Single-arm, Open-label Trial of Atezolizumab in Combination of Split-doses of Gemcitabine Plus Cisplatin in Patients With Locally Advanced or Metastatic Urothelial CarcinomaStatus: Completed, Estimated PCD: 2024-02-02
Product
AtezolizumabProduct
GemcitabineProduct
CisplatinClinical trial
Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic AlterationsStatus: Recruiting, Estimated PCD: 2024-09-01
Product
Enfortumab VedotinProduct
ErdafitinibClinical trial
Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial ("URANUS")"Status: Recruiting, Estimated PCD: 2024-12-01
Product
Gemcitabine/CisplatinProduct
M-VAC ProtocolClinical trial
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus ObservationStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma Progressing on Platinum-based Chemotherapy and PD1/L1 Inhibitors: the Double Antibody Drug Conjugate (DAD) Phase I TrialStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Product
Enfortumab vedotin-ejfvClinical trial
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)Status: Active (not recruiting), Estimated PCD: 2026-07-01
Drug
mFOLFOX6Drug
T-VECDrug
AtezolizumabDrug
AN0025Clinical trial
An Open Label, Randomized Phase II Study Neoadjuvant Erdafitinib With or Without Atezolizumab in Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (NERA)Status: Withdrawn, Estimated PCD: 2023-11-03
Clinical trial
A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
TazemetostatClinical trial
A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination With Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial CancerStatus: Recruiting, Estimated PCD: 2025-01-21
Product
CabozantinibClinical trial
A Pilot Trial of Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial CarcinomaStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-07-01
Product
SonidegibClinical trial
Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin With Adjuvant Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CarcinomaStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase Ib/II Study of Selinexor Plus Pembrolizumab in Cisplatin-Ineligible or Cisplatin-Refractory Patients With Advanced Urothelial CarcinomaStatus: Recruiting, Estimated PCD: 2024-05-01
Drug
SelinexorClinical trial
Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of RC48-ADC Combined With JS001 in Postoperative Adjuvant Treatment of HER2-positive Upper Tract Urothelial Carcinoma (UTUC)Status: Recruiting, Estimated PCD: 2027-12-01
Product
RC48-ADC and JS001Clinical trial
Tolerability and Activity of Neoadjuvant Infigratinib, an Inhibitor of FGFR, in Upper Tract Urothelial CarcinomaStatus: Completed, Estimated PCD: 2024-04-17
Product
InfigratinibClinical trial
Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid CancersStatus: Recruiting, Estimated PCD: 2028-01-04
Drug
DevimistatDrug
5-FUProduct
HydroxychloroquineClinical trial
A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) in Combination With Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04CStatus: Not yet recruiting, Estimated PCD: 2028-07-28
Product
Sacituzumab tirumotecan